|
Generic Name |
grapiprant |
|
Indication |
Osteoarthritis (dogs) |
|
Seller |
Elanco Animal Health, Inc. (U.S.) |
GALLIPRANT® is a drug for dogs developed from grapiprant, a selective antagonist of the prostaglandin E2 receptor EP4 whose rights were transferred from Pfizer Inc. when RaQualia Pharma was established. It was developed by the licensee, Aratana Pharmaceuticals in the U.S. (now Elanco), and was approved for the relief of pain and inflammation associated with osteoarthritis in dogs. It has become the 10th blockbuster in Elanco's history as a drug with reduced gastrointestinal, kidney and liver side effects, which had been issues with existing anti-inflammatory analgesics.
Osteoarthritis in dogs is a progressive disease that can be caused by a variety of congenital and traumatic conditions, and is reported to affect one in four dogs regardless of their age or type.
GALLIPRANT® has been approved in the U.S., Europe, Japan, and other major markets, and is delivered to dogs around the world to support their health as family members.